Sequenom Files for FDA Clearance of Impact Dx System, Thrombophilia Test | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Wednesday that it has filed for marketing clearance from the US Food and Drug Administration of its Impact Dx System and Impact Dx Factor V Leiden and Factor II Genotyping Test.

The system and test are intended for use in clinical laboratories.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.